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Role of CD20 expression and other pre-treatment risk factors
in the development of infusion-related reactions in patients
with CLL treated with obinutuzumab
Leukemia (2016) 30, 1763–1766; doi:10.1038/leu.2016.41
Infusion-related reactions (IRRs) elicited by therapeutic antibodies
are commonly observed in the treatment of hematologic
malignancies. In contrast to the currently approved type 1
anti-CD20 monoclonal antibodies (mAb) rituximab and ofatumu-
mab, obinutuzumab is different by virtue of being a type 2 anti-
CD20 mAb with increased capacity to induce direct cell death.1–5
The fragment crystallisable (Fc) portion is glycoengineered
(afucosylated), which increases its binding affinity to FcγRIIIA
and FcγRIIIB,1,2 enhancing antibody dependent cellular cytotoxi-
city and phagocytosis with less complement activation.
In the CLL11 trial (NCT01010061, ‘stage 2’), patients with
previously untreated chronic lymphocytic leukemia (CLL) and
co-morbidities were randomized to receive either rituximab or
obinutuzumab administered in combination with chlorambucil.6,7
In the head-to-head comparison of the two antibody-containing
regimens, obinutuzumab treatment resulted in a statistically
significant improvement in efficacy endpoints. However, this
improvement was accompanied by an increase in IRRs, with
higher overall incidence and severity when compared with the
rituximab-treated arm but largely limited to the first infusion.
These IRRs had clinical importance resulting in a 7% discontinua-
tion rate in the obinutuzumab-treated cohort, compared with
o1% for rituximab. Predisposing biologic and clinical risk factors
for IRRs are not well defined. In an attempt to better understand
the profile of patients with CLL at particular risk of IRRs, we used
this large clinical data set to perform a multivariate analysis.
Patients treated with a first infusion of obinutuzumab (n= 331)
or rituximab (n= 326) were included. Plausible baseline risk factors
were identified a priori and included parameters of disease
burden, patient-specific factors such as age, concurrent medica-
tions and co-morbidities, FcγR genotype and baseline laboratory
values. The primary outcome, development of IRR with the first
infusion, was defined as the occurrence of related signs and
symptoms during or within 24 h of administration.
Multivariable logistic regression models were fit to assess
associations between patient characteristics and early IRR. The
robustness of the model generated was then internally verified
using bootstrapping techniques. A landmark analysis was
performed to evaluate the impact of early IRR on progression-
free survival (PFS) in both groups and Kaplan–Meier curves were
used to illustrate the estimated conditional progression-free
probabilities. All statistical analyses were conducted in SAS (SAS
Institute, Cary, NC, USA).
The incidence of any grade IRR with the first infusion (all grades)
was 65% (214/331) in the obinutuzumab-treated cohort and 27%
(88/326) in the rituximab-treated cohort. Severe IRR (grade⩾ 3)
events were seen in 20% (65/331) of patients treated with
obinutuzumab and 3% (10/326) in the rituximab arm; there were
no fatal IRRs. The features at baseline associated with increased
risk of developing an IRR from obinutuzumab or rituximab were:
higher density of CD20 expression on CD19+CD5+ CLL cells,
increased CD16 (FcγRIIIA) expression on circulating CD56+ natural
killer (NK) cells, palpable splenomegaly, higher absolute lympho-
cyte count (ALC) in peripheral blood (PB), neutropenia, a higher
affinity FcγR genotype (VV or VF versus FF) and the presence of an
underlying respiratory co-morbidity. Odds ratios (ORs) and 95%
confidence intervals (CIs), based on complete case analysis,
are presented in Table 1.
Since IRRs were more frequent and severe in obinutuzumab-
treated patients, we next focused on this group exclusively.
If patients treated with rituximab were excluded from the data set,
the variable that contributed most to the probability of develop-
ing an IRR was the density of CD20 expression on CLL cells in PB
as expressed by the mean fluorescent intensity (MFI) generated by
flow cytometric analysis pre-treatment (OR 3.6, 95% CI 1.6–7.9).
In addition, MFI of CD16 (OR 2.2, 95% CI 0.8–5.6) on gated NK cells
and the presence of a palpable spleen (OR 1.1, 95% CI 0.98–1.2)
retained significance. Other variables including baseline neutro-
phil count, ALC, the presence of respiratory co-morbidities and
FcγR genotype did not appear to influence outcome to the same
degree when rituximab-treated patients were excluded.
To externally validate the importance of CD20 MFI as
a risk factor, data from any available prior trials involving
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CLL patients treated with either rituximab or obinutuzumab where
pre-treatment MFI CD20 was obtained (n= 935) were pooled
(NCT01010061,6 NCT01414205,8 NCT01300247(ref. 9) and
NCT0028191810). Only severe (grade⩾ 3) IRRs were analyzed
as grades 1 and 2 had not been collected uniformly in all the
trials available. Results were standardized and plotted for those
patients treated with either obinutuzumab or rituximab and
those patients who experienced reactions were identified
(Supplementary Figure 1). Patients with higher baseline
expression CD20 on their CLL cells were at greater risk for severe
grade early IRR, especially those patients treated with obinutuzu-
mab (P= 0.02).
As MFIs for CD20 and CD16 are not standardized or routinely
available outside the setting of clinical trials, we performed
a separate analysis on the CLL11 data set excluding the
immunophenotyping data, with a focus on the obinutuzumab-
treated patients only. The resulting model was significant for
the presence of trisomy 12 being associated with increased risk
Table 1. Risk factors identified by IRR prediction model using the CLL11 data set
Risk factor ORa 95% CIa Significance retained with bootstrapping




CD20 MFIb expressed on CLL cells at baseline 3.5 1.9–6.7 98
CD16 MFIb on NK (CD56+CD16+) gated cells at
baseline
3.2 1.5–6.8 97
Baseline neutrophil countb (x109/l) 0.31 0.15–0.63 87
FcγRIIIA genotype (position 158) FV versus FF 1.8 1.1–2.8 80 (overall)
FcγRIIIA genotype (position 158) VV versus FF 2.3 1.1–5.2
Splenomegaly (as measured by physical examination
in cm below costal margin)
1.1 1.01–1.15 84
Baseline ALCb (x109/l) 1.8 1.03–3.0 65
Presence of respiratory co-morbidity Yes/no 1.7 1.07–2.7 73
Abbreviations: ALC, absolute lymphocyte count; CI, confidence interval; CLL, chronic lymphocytic lymphoma; IRR, infusion-related reaction; MFI, mean
fluorescence intensity; NK, natural killer; OR, odds ratio. a41 implies increased risk, o1 implies reduced risk for increasing values of risk factor. bVariables were
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Figure 1. Prognostic significance of IRR in patients treated with anti-CD20 monoclonal antibodies. (a) Landmark analysis (starting day 3) of
rituximab-treated patients. HR= 0.6, 95% CI 0.4–0.8, P= 0.002; (b) Landmark analysis (starting day 3) of obinutuzumab-treated patients.
HR= 1.5, 95% CI 1.0–2.4, P= 0.07; (c) Landmark analysis of patients treated with 6 cycles of rituximab. HR= 0.7, 95% CI 0.5–0.9, P= 0.01;
(d) Landmark analysis of patients treated with 6 cycles of obinutuzumab. HR= 1.5, 95% CI 0.9–2.6, P= 0.1.
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(OR 2.1, 95% CI 1.02–4.2) along with splenomegaly (OR 1.1, 95%
CI 1.0–1.2) and baseline thrombocytopenia (OR 2.2, 95% CI 1.2–
4.2). Of those patients with trisomy 12, 41/55 experienced an IRR
(Po0.05) compared with those without this cytogenetic
abnormality.
To assess if the development of early IRR influenced outcome
for patients treated with anti-CD20 mAbs, a landmark analysis was
performed starting at study day 3 to eliminate the impact
of patients who discontinued immediately with the first infusion.
Prognostic factors at baseline that might otherwise influence
PFS11 were relatively balanced across all groups (Supplementary
Table 1). For patients treated with rituximab (Figure 1a), there
appeared to be a statistically significant benefit conferred, with
improved PFS in those patients who experienced an early IRR
(hazard ratio (HR) 0.6, 95% CI 0.4–0.8, P= 0.002). For those
patients treated with obinutuzumab, all patients had improved
PFS compared with those treated with rituximab, but there
appeared to be no benefit from having an early IRR in this cohort
(HR 1.5, 95% CI 1.0–2.4, P= 0.07) with no statistically significant
difference between the two groups (Figures 1b). Including only
patients that received all six cycles of therapy yielded similar
results—a statistically significant benefit seen in those
who experienced early IRR treated with rituximab (HR 0.7, 95%
CI 0.5–0.9, P= 0.01) but no significant difference seen in those
treated with obinutuzumab (HR 1.5, 95% CI 0.9–2.6, P= 0.1;
Figures 1c and d).
This analysis, based on a large number of treatment-naïve CLL
patients, has identified novel disease- and patient-specific biologic
variables that appear to play a role in the development of IRR with
anti-CD20 mAbs. Increased expression of CD20 on the surface of
CLL cells at baseline was found to be a consistently important
determinant of risk, a finding that we were able to validate with
both internal and external data sets. When this variable was
excluded for obinutuzumab-treated patients, the presence of
Trisomy 12, known to be associated with higher levels of CD20
expression in CLL12,13 became statistically significant. In the
absence of standardized methods of assessing and reporting
CD20 MFI at the present time, this cytogenetic abnormality may
prove a useful surrogate to identify patients at particular risk
of IRR.
The risk factors of greatest importance would suggest that IRR
result from enhanced binding of anti-CD20 biologics to both
malignant B-cells and the FcγR of NK cells. The natural conclusion
was that this would result in greater cytotoxicity and improve-
ments in progression-free outcomes for patients. Increased levels
of CD20 expression have been correlated with improved response
to therapy,14 and for those patients treated with rituximab, the
development of IRR was associated with improved response.
However for patients treated with obinutuzumab, although PFS
curves demonstrated consistent superiority over rituximab, the
development of IRR did not appear to confer significant
advantage in PFS in our analysis. The occurrence of IRR
in rituximab-treated patients may well herald improved efficacy,
whereas this improved efficacy was observed in all patients
treated with the more potent type 2 antibody obinutuzumab, in
whom the majority (66%) experienced IRR. It is important to
acknowledge that patients were not randomized to having an IRR
and this hypothesis generating analysis will need to be further
evaluated.
Our results support the idea that higher rates of IRR seen with
the administration of obinutuzumab result from cellular activation
and enhanced cross-linking between CD20 expressing leukemic
cells and FcγRIIIA bearing effector cells—an on-target effect. As
external validation was limited and models were derived using a
single data set, these results will need to be corroborated with the
generation of further patient data from ongoing clinical studies.
The improvement in antibody technology realized by obinutuzumab
can confer benefit to more patients if we can better understand how
to predict, manage and prevent IRR. This is currently the subject
of evaluation in ongoing clinical trials (NCT01905943 and
NCT02336048) and these results may shed more light on how
best to prevent this immunologic phenomenon.
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Familial associations of monoclonal gammopathy of unknown
significance with autoimmune diseases
Leukemia (2016) 30, 1766–1769; doi:10.1038/leu.2016.43
Monoclonal gammopathy of undetermined significance (MGUS)
is an asymptomatic premalignant clonal condition, which is diagnosed
often fortuitously, through high levels of immunoglobulin-derived
serum M-protein produced by a plasma cell clone.1,2 The prevalence
of MGUS increases with age, and in predominantly white popula-
tions, it increases from 3% at age 60 years to 9% at age 80–89 years.3
MGUS is a precursor condition for multiple myeloma (MM) and light
chain amyloidosis, which are progressive conditions with a fatal
outcome. Both MGUS and MM show familial clustering among and
between these diseases, suggesting that they share genetic
susceptibility; MGUS is also related to some other malignancies of
the B-cell lineage.4–7 Known nongenetic risk factors of MGUS
include prior infections and exposure to herbicides.8–10 Studies on
the association of MGUS with personal or familial autoimmune
diseases (ADs) have shown several associations for personal
history, whereas for family history of combined ADs, the risk of 1.1
was reported.9,11 For MM, both personal and family histories with
certain ADs have been identified.9,11,12 However, the risk for MM
has been overall small (1.1), and found only in ankylosing
spondylitis and systemic sclerosis patients.12
For the present study, we identified 12 140 MGUS patients from
Swedish nationwide hospital records, and from the same sources,
we identified 769 991 patients with any of 43 ADs. Combining
these into a nationwide family register, we provide familial risk for
MGUS patients whose first-degree relatives were diagnosed with
ADs. Conversely, we also calculated risks for AD patients whose
family members were diagnosed with MGUS to yield a largely
independent risk estimate. Because of large sex-preference among
ADs, sex-specific familial risks were also shown.
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